Biogen (BIIB) Tops Q2 EPS by $1.48, Beats on Revenue; Offers Guidance
Tweet
Share
E-mail
Get Alerts BIIB Hot Sheet
Price: $209.74 --0%
EPS Growth %: -41.3%
Financial Fact:
Product: 2.54B
Today's EPS Names:
PKE, LNN, More
EPS Growth %: -41.3%
Financial Fact:
Product: 2.54B
Today's EPS Names:
PKE, LNN, More
Join SI Premium – FREE
(Updated - July 31, 2025 6:06 AM EDT)
Biogen (NASDAQ: BIIB) reported Q2 EPS of $5.47, $1.48 better than the analyst estimate of $3.99. Revenue for the quarter came in at $2.6 billion versus the consensus estimate of $2.32 billion.
The company sees FY25 EPS of $15.50-$16 vs analyst estimate of $14.64.
For earnings history and earnings-related data on Biogen (BIIB) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Biogen expects $164M R&D charge to hit Q2 2026 earnings
- BMO Capital: 'ISM Data Reinforces Constructive Freight Outlook'
- Freedom Broker Starts Arcturus Therapeutics (ARCT) at Buy
Create E-mail Alert Related Categories
Corporate News, Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
